Veradermics Gets a $136 Price Target — 33% Above Current Price
NEW YORK, June 2 —
Oppenheimer initiated Veradermics (MANE) with a bullish rating and a $136 price target, implying 33% upside to a stock that has not yet turned a profit.
- $136 price target vs. $102.05 current price — 33% implied upside from Oppenheimer's initiation
- Forward P/E of -34.0x: no earnings to anchor the valuation; this is a growth and pipeline bet
- Watch for follow-on initiations in the next 30 days — that is when Oppenheimer's conviction gets tested by the street
What Actually Happened
Oppenheimer ranked MANE among its top five initiations of the day. That is not a routine sector add. It signals elevated internal conviction, which matters here because the stock offers no earnings cushion to justify a position on fundamentals alone.
Here is what CNBC will skip: for a pre-profit name, the price target is almost secondary to the visibility. Once Oppenheimer's coverage goes live, the stock appears in Bloomberg screeners, options market makers tighten spreads, and institutional compliance desks can green-light a position they previously had to pass on. That structural shift in who can own it is the real event today.
The $136 figure gives portfolio managers a valuation anchor to write up in a memo. The initiation gives them permission to buy.
The Catch
A forward P/E of -34.0x means Veradermics is not profitable on a projected basis. Oppenheimer's $136 is not a multiple on earnings — it is built on something else: a revenue ramp, a pipeline event, or an addressable market argument that has not yet shown up in the income statement.
That is a fundamentally different risk profile than a coverage initiation on a cash-generating business. If the catalyst Oppenheimer is pricing does not land on schedule, the downside from $102 has no value floor to catch it.
Bottom Line
Growth investors willing to own a pre-profit name with fresh institutional sponsorship now have a credible entry thesis. Value investors have nothing to hold onto at -34.0x forward earnings — there is no price-to-earnings ratio to compare against history.
The number to watch is not the $136 target itself but the trajectory toward it. MANE climbing toward $115-$120 on follow-on initiations would confirm the thesis is spreading. A slide back below $95 would signal the market is not buying what Oppenheimer is selling.
Generate a full Basis Report on Veradermics at /stock/mane for the complete financial picture before the next catalyst.
Basis Report does not hold positions in securities discussed. This is not investment advice.